1. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy
- Author
-
Ian Laing, Paul N. Durrington, Hilary Prais, Michael I. Mackness, J Morgan, F. Med Sci, Allen P. Yates, Peter Selby, See Kwok, Bharti Mackness, and Patrick McElduff
- Subjects
Blood Glucose ,Medroxyprogesterone ,medicine.medical_specialty ,Norethisterone ,medicine.drug_class ,Lipoproteins ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Drug Administration Schedule ,Statistics, Nonparametric ,chemistry.chemical_compound ,Endocrinology ,Risk Factors ,Desogestrel ,Internal medicine ,medicine ,Humans ,Insulin ,Risk factor ,Triglycerides ,Progestogen ,Triglyceride ,Aryldialkylphosphatase ,Cholesterol ,business.industry ,Estrogen Replacement Therapy ,Fibrinogen ,Middle Aged ,Postmenopause ,C-Reactive Protein ,chemistry ,Cardiovascular Diseases ,Estrogen ,Female ,Norethindrone ,Progestins ,business ,Biomarkers ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
Summary objective Medroxyprogesterone (MP) was used as the progestogen in randomized clinical trials of postmenopausal hormone replacement on cardiovascular risk. To attempt to understand the lack of benefit in these trials, we have examined the effects of MP and two other progestogens, the less androgenic desogestrel (DG) and the more androgenic norethisterone (NE), on cardiovascular risk factors against a background of oestrogen therapy. design and measurements Thirty-four women were treated with conjugated equine oestrogens (CEE) 0·625 mg daily alone for 12 weeks, followed in random order by each of the three progestogens (DG 75 µg, MP 10 mg and NE 1 mg daily) given sequentially for three 12-week cycles while maintaining the same CEE treatment. We measured serum lipoproteins, paraoxonase activity, C-reactive protein (CRP), fibrinogen, fasting glucose and insulin levels at baseline, at the end of the oestrogen-only phase and at the end of each of the combined oestrogen and progestogen phases. results The addition of progestogens to CEE maintained the oestrogen-induced reduction in apolipoprotein B (apo B) and lipoprotein (a) [Lp(a)], and further lowered total cholesterol (P
- Published
- 2004